{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T17:53:20Z","timestamp":1790618000950,"version":"4.1.0"},"reference-count":31,"publisher":"SAGE Publications","issue":"7","license":[{"start":{"date-parts":[[2025,9,3]],"date-time":"2025-09-03T00:00:00Z","timestamp":1756857600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2025,9,3]],"date-time":"2025-09-03T00:00:00Z","timestamp":1756857600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"funder":[{"DOI":"10.13039\/501100001826","name":"ZonMw","doi-asserted-by":"publisher","award":["0-82310-97-11031"],"award-info":[{"award-number":["0-82310-97-11031"]}],"id":[{"id":"10.13039\/501100001826","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013891","name":"Parkinson Vereniging","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013891","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008383","name":"Stichting ParkinsonFonds","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008383","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Stichting Parkinson Nederland"},{"DOI":"10.13039\/100016853","name":"Lysosomal Disease Network","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016853","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Journal of Parkinson\u2019s Disease"],"published-print":{"date-parts":[[2025,11]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      This study presents post-hoc analyses of the LEAP study focusing on disease progression in patients with early Parkinson's disease (PD) who either have a glucocerebrosidase gene (\n                      <jats:italic toggle=\"yes\">GBA1<\/jats:italic>\n                      ) mutation (GBA1mut) or do not have a mutation (GBA1wt) over a period of up to five years.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To investigate the difference in disease progression between GBA1mut and GBA1wt over 80 weeks and five years.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>The study analyzed the difference in disease progression between GBA1mut and GBA1wt using the UPDRS and its subscales, Levy A and B scores, and the difference in levodopa equivalent daily dose (LEDD) over 80 weeks and five years, with mixed-effects regression models.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The\n                      <jats:italic toggle=\"yes\">GBA1<\/jats:italic>\n                      mutation carrier status was determined in 394 patients, with 52 being GBA1mut and 342 being GBA1wt. From baseline to 80 weeks, the change in total UPDRS score was similar for GBA1mut and GBA1wt (difference 1.7 points in favor of GBA1mut, p\u2009=\u20090.38). From baseline to five years, GBA1mut had 5.9 points (p\u2009=\u20090.04) more worsening of total UPDRS compared to GBA1wt and GBA1mut had 1.0 point (p\u2009=\u20090.02) more deterioration in UPDRS subscale IV, related to therapy complications, compared to GBA1wt. There were no significant between-group differences in changes in UPDRS subscales, Levy A and B scores, and LEDD.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>\n                      These findings suggest that over the long term, PD patients with a\n                      <jats:italic toggle=\"yes\">GBA1<\/jats:italic>\n                      mutation experience faster disease progression compared to those without a\n                      <jats:italic toggle=\"yes\">GBA1<\/jats:italic>\n                      mutation, although this difference in progression was not apparent within the initial 80 weeks of the trial.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/1877718x251361507","type":"journal-article","created":{"date-parts":[[2025,9,3]],"date-time":"2025-09-03T12:56:54Z","timestamp":1756904214000},"page":"1208-1217","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":1,"title":["Faster disease progression in Parkinson's disease with glucocerebrosidase genotype: But not apparent immediate from diagnosis"],"prefix":"10.1177","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2203-790X","authenticated-orcid":false,"given":"Henrieke L","family":"Frequin","sequence":"first","affiliation":[{"name":"Department of Neurology, Amsterdam University Medical Center (Amsterdam UMC), Amsterdam Neuroscience, University of Amsterdam, Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7050-5931","authenticated-orcid":false,"given":"Bart","family":"Ferwerda","sequence":"additional","affiliation":[{"name":"Department of Clinical Epidemiology and Biostatistics, Amsterdam University Medical Center (Amsterdam UMC), University of Amsterdam, Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7234-6567","authenticated-orcid":false,"given":"Constant VM","family":"Verschuur","sequence":"additional","affiliation":[{"name":"Department of Neurology, Albert Schweitzer ziekenhuis, Dordrecht, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sven R","family":"Suwijn","sequence":"additional","affiliation":[{"name":"Department of Neurology, Amsterdam University Medical Center (Amsterdam UMC), Amsterdam Neuroscience, University of Amsterdam, Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8972-1530","authenticated-orcid":false,"given":"Joke M","family":"Dijk","sequence":"additional","affiliation":[{"name":"Department of Neurology, Amsterdam University Medical Center (Amsterdam UMC), Amsterdam Neuroscience, University of Amsterdam, Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5267-0784","authenticated-orcid":false,"given":"Rob MA","family":"de Bie","sequence":"additional","affiliation":[{"name":"Department of Neurology, Amsterdam University Medical Center (Amsterdam UMC), Amsterdam Neuroscience, University of Amsterdam, Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"for the LEAP Study Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2025,9,3]]},"reference":[{"key":"e_1_3_3_2_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0901281"},{"key":"e_1_3_3_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(12)70190-4"},{"key":"e_1_3_3_4_2","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/aws318"},{"key":"e_1_3_3_5_2","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awp044"},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0167749"},{"key":"e_1_3_3_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.neurobiolaging.2015.08.027"},{"key":"e_1_3_3_8_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e318225ab77"},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.1002\/mds.24045"},{"key":"e_1_3_3_10_2","doi-asserted-by":"publisher","DOI":"10.1002\/ana.24777"},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000011411"},{"key":"e_1_3_3_12_2","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000304039.11891.29"},{"key":"e_1_3_3_13_2","doi-asserted-by":"publisher","DOI":"10.1002\/mds.26071"},{"key":"e_1_3_3_14_2","doi-asserted-by":"publisher","DOI":"10.1002\/ana.24781"},{"key":"e_1_3_3_15_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2016.2245"},{"key":"e_1_3_3_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.parkreldis.2019.11.015"},{"key":"e_1_3_3_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(20)30036-3"},{"key":"e_1_3_3_18_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1809983"},{"key":"e_1_3_3_19_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12883-015-0491-1"},{"key":"e_1_3_3_20_2","first-page":"153","volume-title":"Recent developments in Parkinson's disease","author":"Fahn S","year":"1987","unstructured":"Fahn S, Elton R; Members of the UPDRS Development Committee. Unified Parkinson's disease rating scale. In: Marsden CD, Calne DB, Goldstein M (eds) Recent developments in Parkinson's disease. 2nd ed. Florham Park, NJ: Macmillan Health Care Information, 1987, pp.153\u2013163, pp. 293\u2013304.","edition":"2"},{"key":"e_1_3_3_21_2","doi-asserted-by":"publisher","DOI":"10.1002\/mdc3.12921"},{"key":"e_1_3_3_22_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.55.4.539"},{"key":"e_1_3_3_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/0022-3956(75)90026-6"},{"key":"e_1_3_3_24_2","doi-asserted-by":"publisher","DOI":"10.1002\/mds.20153"},{"key":"e_1_3_3_25_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1532-5415.2005.53221.x"},{"key":"e_1_3_3_26_2","doi-asserted-by":"publisher","DOI":"10.1093\/bioinformatics\/btp324"},{"key":"e_1_3_3_27_2","doi-asserted-by":"publisher","DOI":"10.1101\/gr.107524.110"},{"key":"e_1_3_3_28_2","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-17-0337"},{"key":"e_1_3_3_29_2","doi-asserted-by":"publisher","DOI":"10.1097\/00001648-199001000-00010"},{"key":"e_1_3_3_30_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000001953"},{"key":"e_1_3_3_31_2","doi-asserted-by":"publisher","DOI":"10.3233\/JPD-212657"},{"key":"e_1_3_3_32_2","doi-asserted-by":"publisher","DOI":"10.1002\/mds.27882"}],"container-title":["Journal of Parkinson\u2019s Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1877718X251361507","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/1877718X251361507","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1877718X251361507","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T22:51:53Z","timestamp":1777589513000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/1877718X251361507"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,3]]},"references-count":31,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["10.1177\/1877718X251361507"],"URL":"https:\/\/doi.org\/10.1177\/1877718x251361507","relation":{},"ISSN":["1877-7171","1877-718X"],"issn-type":[{"value":"1877-7171","type":"print"},{"value":"1877-718X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,3]]}}}